152 related articles for article (PubMed ID: 16363036)
1. Gray area for new heart failure drug. Although the FDA approved BiDil for blacks with heart failure, it may work in anyone.
Harv Heart Lett; 2005 Nov; 16(3):1-2. PubMed ID: 16363036
[No Abstract] [Full Text] [Related]
2. Bidil: recontextualizing the race debate.
Séguin B; Hardy B; Singer PA; Daar AS
Pharmacogenomics J; 2008 Jun; 8(3):169-73. PubMed ID: 18195727
[No Abstract] [Full Text] [Related]
3. BiDil for heart failure in black patients.
Kahn JD
Ann Intern Med; 2007 Aug; 147(3):215; author reply 215-6. PubMed ID: 17679713
[No Abstract] [Full Text] [Related]
4. BiDil for heart failure in black patients.
Bibbins-Domingo K; Fernandez A
Ann Intern Med; 2007 Aug; 147(3):214-5; author reply 215-6. PubMed ID: 17679712
[No Abstract] [Full Text] [Related]
5. FDA approves heart drug for black patients.
Meadows M
FDA Consum; 2005; 39(5):8-9. PubMed ID: 16419285
[TBL] [Abstract][Full Text] [Related]
6. The paradox of race in the Bidil debate.
Crawley L
J Natl Med Assoc; 2007 Jul; 99(7):821-2. PubMed ID: 17668653
[No Abstract] [Full Text] [Related]
7. "Special treatment": BiDil, Tuskegee, and the logic of race.
Reverby SM
J Law Med Ethics; 2008; 36(3):478-84. PubMed ID: 18840239
[TBL] [Abstract][Full Text] [Related]
8. Introduction: Facts and fictions: BiDil and the resurgence of racial medicine.
Dorr GM; Jones DS
J Law Med Ethics; 2008; 36(3):443-8. PubMed ID: 18840234
[No Abstract] [Full Text] [Related]
9. Color blind, or just plain blind?
Czap A
Altern Med Rev; 2005 Jun; 10(2):81-2. PubMed ID: 16032786
[No Abstract] [Full Text] [Related]
10. Not black and white: BiDil may work best for African Americans--but do we know why?
New Sci; 2005 Jun 11-17; 186(2503):3. PubMed ID: 16178098
[No Abstract] [Full Text] [Related]
11. BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective.
Temple R; Stockbridge NL
Ann Intern Med; 2007 Jan; 146(1):57-62. PubMed ID: 17200223
[TBL] [Abstract][Full Text] [Related]
12. Race-based therapeutics.
Bloche MG
N Engl J Med; 2004 Nov; 351(20):2035-7. PubMed ID: 15533852
[No Abstract] [Full Text] [Related]
13. Flaws in the U.S. Food and Drug Administration's rationale for supporting the development and approval of BiDil as a treatment for heart failure only in black patients.
Ellison GT; Kaufman JS; Head RF; Martin PA; Kahn JD
J Law Med Ethics; 2008; 36(3):449-57. PubMed ID: 18840235
[TBL] [Abstract][Full Text] [Related]
14. BiDil for heart failure.
Med Lett Drugs Ther; 2005 Sep; 47(1218):77-8. PubMed ID: 16186789
[TBL] [Abstract][Full Text] [Related]
15. BiDil for heart failure in black patients: implications of the U.S. Food and Drug Administration approval.
Bibbins-Domingo K; Fernandez A
Ann Intern Med; 2007 Jan; 146(1):52-6. PubMed ID: 17200222
[TBL] [Abstract][Full Text] [Related]
16. Prescribing BiDil: is it black and white?
Haga SB; Ginsburg GS
J Am Coll Cardiol; 2006 Jul; 48(1):12-4. PubMed ID: 16814642
[TBL] [Abstract][Full Text] [Related]
17. Grassroots marketing in a global era: more lessons from BiDil.
Rusert BM; Royal CD
J Law Med Ethics; 2011; 39(1):79-90. PubMed ID: 21314797
[No Abstract] [Full Text] [Related]
18. Colour-coded cures.
Kingsland J
New Sci; 2005 Jun 11-17; 186(2503):42-7. PubMed ID: 16178100
[No Abstract] [Full Text] [Related]
19. BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients.
Carmody MS; Anderson JR
Cardiol Rev; 2007; 15(1):46-53. PubMed ID: 17172884
[TBL] [Abstract][Full Text] [Related]
20. U.S. to review drug intended for one race.
Saul S
N Y Times Web; 2005 Jun; ():A1, A15. PubMed ID: 15966118
[No Abstract] [Full Text] [Related]
[Next] [New Search]
